1. Home
  2. Earnings Beat
  3. Will Trinity Biotech Stock Gain From Its Latest Patent Process?

Will Trinity Biotech Stock Gain From Its Latest Patent Process?

2
0

Trinity Biotech plc (NASDAQ: TRIB) recently provided an update on its continued development of its glucose biosensor technology. Earlier this year, the company was granted a European patent for a novel method that enhances the performance of its glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of the sensor.

Trinity Biotech intends to use this breakthrough process to stabilize and improve the functionality of its glucose biosensor in its next-generation continuous glucose monitor (CGM) technology.

Shares of TRIB went down marginally by 0.05% in pre-market trading today following the news. However, as the company is gaining a high level of synergies from its continued development within the CGM market, this latest development might prove fruitful in strengthening its foothold in this space. Accordingly, we expect market sentiment to recover shortly.

Significance of Trinity Biotech’s Patented Process

CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real time. Generally, these devices experience a “run-in” or “settling” period immediately after their insertion. During the run-in period, glucose readings are unreliable. 

Trinity Biotech’s patent describes a unique process within the company’s reusable transmitter unit that “conditions” the CGM biosensor wire. This conditioning process significantly reduces this run-in time, enabling reliable measurements more quickly. 

Additionally, the conditioning process has demonstrated notable improvements in the accuracy of the CGM device compared to …

Full story available on Benzinga.com

Visited 2 times, 1 visit(s) today